93 related articles for article (PubMed ID: 27580959)
1. Myeloproliferative neoplasms: association with lymphoproliferative disorders; a single institution experience.
Batt T; Tegg E; Johnston A
Pathology; 2016 Oct; 48(6):637-9. PubMed ID: 27580959
[No Abstract] [Full Text] [Related]
2. Retrospective epidemiological study of hemopoietic system neoplasms in Argentina.
Quiroga Micheo E; Calcagno EJ; Calabria SI; Besuschio SC; Magnasco JH; Sackmann Muriel F; Maccione E; Barros C; Santoro A; de Soto ZC
Medicina (B Aires); 1981; 41(2):187-200. PubMed ID: 7278616
[No Abstract] [Full Text] [Related]
3. [Organization and the 1st results of the work of a registry of hemoblastoses].
Lebedeva IuL; Lapin BA; Lebedev VN; Bologov VN; Broun VK
Probl Gematol Pereliv Krovi; 1979 Apr; 24(4):50-7. PubMed ID: 432237
[No Abstract] [Full Text] [Related]
4. [Epidemiology of hemoblastosis].
Gus'kova AK
Probl Gematol Pereliv Krovi; 1979 Feb; 24(2):58-9. PubMed ID: 424405
[No Abstract] [Full Text] [Related]
5. Importance of a specialized registry of haematopoietic malignancies.
Carli PM
Nouv Rev Fr Hematol (1978); 1991; 33(2):119-21. PubMed ID: 1766838
[No Abstract] [Full Text] [Related]
6. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: patterns in space and time.
Lickiss JN; Giles GG; Baikie MJ; Lowenthal RM; Challis D; Panton J
J Natl Cancer Inst; 1984 Jun; 72(6):1223-31. PubMed ID: 6587144
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects.
Giles GG; Lickiss JN; Baikie MJ; Lowenthal RM; Panton J
J Natl Cancer Inst; 1984 Jun; 72(6):1233-40. PubMed ID: 6587145
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France.
Hausfater P; Cacoub P; Sterkers Y; Thibault V; Amoura Z; Nguyen L; Ghillani P; Leblond V; Piette JC
Am J Hematol; 2001 Jul; 67(3):168-71. PubMed ID: 11391713
[TBL] [Abstract][Full Text] [Related]
9. [Morbidity of leukemia and other hemoblastoses in an urban population].
Baziian GV; Podgornykh LK
Vopr Onkol; 1982; 28(7):67-72. PubMed ID: 7101832
[TBL] [Abstract][Full Text] [Related]
10. [Principles and results of 5 years' work on a register of hemoblastoses].
Lapin BA; Lebedeva IuL; Lebedev VN; Iakovleva LA; Finchenko GA
Vopr Onkol; 1980; 26(1):18-23. PubMed ID: 6444476
[TBL] [Abstract][Full Text] [Related]
11. Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study.
Lowenthal RM; Tuck DM; Bray IC
Intern Med J; 2007 Sep; 37(9):614-9. PubMed ID: 17543004
[TBL] [Abstract][Full Text] [Related]
12. Association of myeloproliferative and lymphoproliferative disorders.
Gaillard JB; Carillo S; Henry L; Jourdan E; Lavabre-Bertrand T
Clin Adv Hematol Oncol; 2012 Nov; 10(11):756-7. PubMed ID: 23271265
[No Abstract] [Full Text] [Related]
13. Clinical and pathological characterization of posttransplantation lymphoproliferative disorders in kidney transplant recipients: single institution experience.
Rojas G; Alberú J; Bordes-Aznar J; Quintanilla-Martínez L; Lome-Maldonado MC; Cesarman G; Angeles-Angeles A; Correa-Rotter R
Transplant Proc; 1996 Dec; 28(6):3317-20. PubMed ID: 8962289
[No Abstract] [Full Text] [Related]
14. Familial malignant blood disease in the country of Jämtland, Sweden.
Eriksson M; Bergström I
Eur J Haematol; 1987 Mar; 38(3):241-5. PubMed ID: 3595812
[TBL] [Abstract][Full Text] [Related]
15. Liver biopsy diagnosis of unsuspected or unconfirmed lymphoproliferative or myeloproliferative disorders.
Ludwig J; Boon SE
Hepatogastroenterology; 1980 Feb; 27(1):17-25. PubMed ID: 7203353
[TBL] [Abstract][Full Text] [Related]
16. What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?
Mirheydar HS; Banapour P; Massoudi R; Palazzi KL; Jabaji R; Reid EG; Millard FE; Kane CJ; Sur RL
Int Braz J Urol; 2014; 40(6):772-80. PubMed ID: 25615245
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders.
Shirin H; Davidovitz Y; Avni Y; Petchenko P; Krepel Z; Bruck R; Meytes D
Isr Med Assoc J; 2002 Jan; 4(1):24-7. PubMed ID: 11802304
[TBL] [Abstract][Full Text] [Related]
18. Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders.
Paulino AC; Reddy SP
Am J Hosp Palliat Care; 1996; 13(6):32-5. PubMed ID: 8945101
[TBL] [Abstract][Full Text] [Related]
19. [Incidence of haematological neoplasms in Castilla y León, Spain].
Rodríguez-García JA; Vázquez L; Ramos F; Cuevas B; Martín A; Smucler A; Guerola DN; Cantalapiedra A; Alonso JM; Fernández S; Díez E; Rodríguez MJ; Calmuntia MJ; Aguilar C; Sierra M; Gracia JA; Cebeira MJ; Cantalejo R;
Med Clin (Barc); 2015 Jun; 144(11):491-500. PubMed ID: 25015251
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of antibodies to hepatitis C virus in patients with lymphoproliferative disorders.
Cavanna L; Sbolli G; Tanzi E; Romanò L; Civardi G; Buscarini E; Vallisa D; Berté R; Rossi A
Haematologica; 1995; 80(5):486-7. PubMed ID: 8566896
[No Abstract] [Full Text] [Related]
[Next] [New Search]
